戊型肝炎肝衰竭死亡原因分析*

doi:10.3969/j.issn.1672-5069.2019.02.017

摘要/Abstract

摘要： 目的分析影响戊型肝炎肝衰竭患者预后的影响因素,为其防治提供经验。方法 2009年3月~2016年3月收治的慢加急性戊型肝炎肝衰竭患者140例,经内科综合治疗后生存63例,死亡77例。回顾性分析生存与死亡患者肝功能指标,采用Logistic多元回归分析进行单因素和多因素分析影响预后的危险因素。结果死亡组血清甲胎蛋白峰值水平仅为（47.6±8.9） ng/ml,显著低于生存组[（175.8±254.1） ng/ml,P<0.05],血清总胆红素峰值水平为（377.3±164.6） μmol/L,显著高于生存组[（251.7±151.4） μmol/L,P<0.05],凝血酶原时间国际标准化比值（INR）为（2.4±0.6）,显著高于生存组【（1.6±0.2）,P<0.001】,血清白蛋白水平为（32.2±9.9） g/L,显著低于生存组【（35.8±8.2） g/L,P<0.05】;单因素分析结果显示,年龄大于60岁（P<0.001）、有肝脏基础疾病（P=0.032）、并发肝性脑病（P=0.024）、存在感染（P=0.03）、并发消化道出血（P=0.014）、有腹水（P=0.02）为影响慢加急性戊型肝炎肝衰竭患者预后的危险因素;多因素回归分析结果显示,肝性脑病（P=0.005）、感染（P<0.001）、消化道出血（P=0.001）和基础肝病（P=0.004）是影响慢加急性戊型肝炎肝衰竭患者预后的独立危险因素。结论部分戊型肝炎患者会发展至肝衰竭,以慢加急性肝衰竭为多见,内科综合治疗仅在不到一半的患者有效,而血清胆红素水平和INR太高患者预后不良,并发肝性脑病、感染、消化道出血和有基础肝病是影响慢加急性戊型肝炎肝衰竭患者预后的独立危险因素,可作为判断肝衰竭患者预后的临床指标,对此类患者应进行积极的护理和治疗,预防并发症的发生,以提高患者生存率。

关键词: 肝衰竭, 戊型肝炎, 预后, 影响因素

Abstract: Objective To analyze the risk factors for poor prognosis of patients with hepatitis E-induced liver failure. Methods 140 patients with hepatitis E-induced liver failure were admitted to our hospital between March 2009 and March 2016. 63 patients survived and 77 died. The independent risk factors for poor prognosis were analyzed by univariate and multivariate Logistic analysis. Results The peak serum alpha-fetoprotein level in dead patients was（47.6±8.9） ng/ml,significantly lower than（175.8±254.1） ng/ml（P<0.05） in the survival,total serum bilirubin level was（377.3±164.6） μmol/L,much higher than （251.7±151.4） μmol/L （P<0.05） in the survival,the INR was（2.4±0.6）,much higher than[（1.6±0.2）,P<0.001] in the survival,while serum albumin level was （32.2±9.9） g/L,significantly lower than（35.8±8.2）g/L （P<0.05） in the survival;univariate analysis showed that older than 60 year （P<0.001）,with underlying liver disease （P=0.032）,complicated by hepatic encephalopathy （HE,P=0.024）,infection （P=0.03）,gastrointestinal bleeding （GIB,P=0.014） and with ascites （P=0.02） were the related factors impacting prognosis,and multivariate Logistic analysis demonstrated that HE （P=0.005）,infection （P<0.001）,GIB（P=0.001） and underlying liver disease（P=0.004） were the independent risk factors for poor prognosis of patients with hepatitis E-induced chronic-on-acute liver failure. Conclusion Some patients with hepatitis E would deteriorate to liver failure,and the chronic-on-acute are common. About fifty percent of the patients survive with conventional supporting treatment,and patients with hyperbilirubinemia and extremely elevated INR would have poor prognosis,especially in patients with underlying liver diseases and complicated by HE, infection and GIB. Clinicians should take this into consideration to deal with the patients with hepatitis E at risk carefully for improvement of prognosis.

Key words: Hepatic failure, Hepatitis E, Prognosis, Influencing factors

高朋彬,赵晓彦,秦浩,吴凤影,钟海振,王琳,贾慧娜,李树娟. 戊型肝炎肝衰竭死亡原因分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 220-223.

Gao Pengbin, Zhao Xiaoyan, Qin Hao, Wu Fengying, Zhang Haizhen, Wang Lin, Jia Huina, Li Shujuan. Risk factors for poor prognosis of patients with hepatitis E-induced liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 220-223.

参考文献

[1] Schlauder GG,Desai SM,Zanetti AR,et al.Novel hepatitis E virus(HEV) isolates from Europe:evidence for additional genotypes of HEV. J Med Virol,2015,57(3):243-251.
[2] Dalton HR,Bendall RP,Keane FE,et al.Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med,2009,361(10):1025-1027.
[3] Ollier L,Tieulie N,Sanderson F,et al.Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med,2009,150(6):430.
[4] Mast EE,Alter MJ,Holland PV,et al.Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E virus antibody serum panel evaluation group. Hepatology,2010,27(3):857-861.
[5] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南.实用肝脏病杂志,2013,16(3):210-216.
[6] Kundra A,Jain AA,Bajaj G,et al.Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem,2005,38(8):696-699.
[7] Zhou RR,Liu HB,Peng JP,et al.High mobility group box chromosomal protein 1 in acute-on-chronic liver failure patients and mice with con A-induced acute liver injury. Exp Mol Patho,2012,93(2):213-219.
[8] Bosoi CR,Rose CF.Brain edema in acute liver failure and chronic liver disease:similarities and differences. Neurochem Int,2013,62(4):446-457.
[9] Qazilbash MH,Qu Z,Hosing C,et al.Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol,2010,80(1):43-45.
[10] Leithead JA,Ferguson JW,Bates C M,et al.Chronic kidney disease after liver transplantation for acute liver failure is not associated with perioperative renal dysfunction. Am J Transplant,2011,11(9):1905-1915.
[11] Steinhorn DM,Alonso EM,Bunchman TE.Acute liver failure,liver transplantation,and extracorporeal liver support. Ped Cri Care,2011,9(7):1248-1258.
[12] Brandsaeter B,Hockerstedt K,Friman S,et al.Fulminant hepatic failure:outcome after listing for highly urgent liver transplantation-12 years experience in the Nordic countries. Liver Transpl,2002,8(11):1055-1062.
[13] Ockner SA,Brunt EM,Cohn SM,et al.Fulminant hepatic failure caused by acute fatty liver of pregnancy treated by orthotopic liver transplantation. Hepatology,2010,11(1):59-64.
[14] Kumar A,Saraswat VA.Hepatitis E and acute-on-chronic liver failure. J Clin Exp Hepatol,2013,3(3):225-230.
[15] 朱明月,郭峻莉,夏华,等. 甲胎蛋白激活PI3K/AKT信号促使肝癌Bel 7402细胞抗全反式维甲酸诱导凋亡. 中华肝脏病杂志,2014,22(11):837-842.
[16] 李道明,李伟,陶敏,等. 蛋白磷酸酶2A催化亚基α显性负性突变体表达载体对肝癌细胞生长的影响. 中华肝脏病杂志,2013,21(6):424-427.
[17] Takikawa Y,Suzuki K.Is AFP a new reliable marker of liver regeneration in acute hepatic failure? J Gastroenterol,2002,37(8):681-682.
[18] Yang SS,Cheng KS,Lai YC,et al.Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B. J Gastroenterol,2002,37(8):626-632.
[19] Ho JK,Tha SP,Coupland R,et al.Parvovirus B19 in an immunocompetent adult patient with acute liver failure:an underdiagnosed cause of acute non-A-E viral hepatitis. Can J Gastroenterol,2016,19(3):161-162.
[20] Arora NK,Nanda SK,Gulati S,et al.Acute viral hepatitis types E,A,and B singly and in combination in acute liver failure in children in North India. J Med Virol,2015,48(3):215-221.
21] Fernández-Montero JV,Barreiro P,Vispo E,et al. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. Aids,2013,27(7):1129-1134.
[22] 李汾香,宋芳丽,郭彩虹. 戊型肝炎104例临床分析. 实用肝脏病杂志,2009,12(6):449-450.

戊型肝炎肝衰竭死亡原因分析^*

Risk factors for poor prognosis of patients with hepatitis E-induced liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[2]	宋海燕, 陈曦, 张骏飞, 方雪晴, 董静, 陈照林, 潘劲劲, 刘波, 陈从新. 伏立康唑治疗肝衰竭并发肺部真菌感染患者疗效初步研究[J]. 实用肝脏病杂志, 2019, 22(5): 676-679.
[3]	张璇, 唐小云, 唐春银, 石学魁, 王惠琦, 张晓东, 沈海萍, 杨春辉. 中药方剂赤白汤对D-氨基半乳糖诱导的急性肝衰竭小鼠肠道菌群的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 478-481.
[4]	庄太平, 尹杨艳, 谢蔓芳, 冯乃超, 陈彩华. 人巨细胞病毒感染与肝炎综合征婴儿临床特点比较^*[J]. 实用肝脏病杂志, 2019, 22(4): 514-517.
[5]	王媛, 党盼玉, 王伟. 血浆置换联合连续性血浆透析滤过治疗慢加急性肝衰竭患者临床疗效及其对血浆细胞因子水平的影响[J]. 实用肝脏病杂志, 2019, 22(4): 541-544.
[6]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[7]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[8]	钟宋, 刘玉元, 刘树人, 周国柱, 刘崇文, 欧阳石. 慢性乙型肝炎患者肝组织自然杀伤细胞G2D表达水平的变化及其临床意义[J]. 实用肝脏病杂志, 2019, 22(3): 341-344.
[9]	潘劲劲, 董静, 宋海燕, 张俊飞, 陈照林, 刘波. 应用糖皮质激素治疗核苷（酸）类似物撤药性肝炎患者临床疗效评价[J]. 实用肝脏病杂志, 2019, 22(3): 357-360.
[10]	杜敏, 周敏, 纪宗淑, 刘海燕, 汤睿, 周亮, 高智. 脓毒症并发肝损伤患者临床特征及其危险因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 369-372.
[11]	德吉, 白玛, 白央, 米玛仓决. 慢性乙型肝炎和肝硬化患者肝脏硬度检测值的变化及其影响因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 401-404.
[12]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[13]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[14]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.
[15]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.